Spectrum Pharmaceuticals, Inc.

NasdaqCM:SPPI 주식 리포트

시가총액: US$209.9m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Spectrum Pharmaceuticals 과거 순이익 실적

과거 기준 점검 0/6

Spectrum Pharmaceuticals 의 수입은 연평균 -0.5%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 33.8%의 비율로 증가했습니다. 매출은 연평균 69.6%의 비율로 감소해 왔습니다.

핵심 정보

-0.47%

순이익 성장률

10.40%

주당순이익(EPS) 성장률

Biotechs 산업 성장률17.04%
매출 성장률-69.57%
자기자본이익률-252.59%
순이익률-263.16%
최근 순이익 업데이트31 Mar 2023

최근 과거 실적 업데이트

업데이트 없음

Recent updates

분석 기사 • May 14

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

Shareholders in Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) may be thrilled to learn that the analysts have just...
분석 기사 • May 12

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) investors will be delighted, with the company turning in some strong...
Seeking Alpha • Sep 20

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

US FDA scientists are concerned about the data Spectrum Pharmaceuticals (NASDAQ:SPPI) has provided to support its drug poziotinib for non-small cell lung cancer ahead of an advisory committee meeting on Thursday. Shares are down 28% in Tuesday morning trading. In a briefing document, the FDA scientists state the data provided shows a low overall response rate (ORR) with minimal duration of response (DOR). ORR was 28% while median DOR was 5.1 months. In addition, they say the safety profile is poor in that at the proposed dosage, 57% of patients experienced dose reductions and 85% of patients had grade 3-4 adverse events. Also, the FDA team faults Spectrum (SPPI) for what it calls inadequate dosage optimization since the company has proposed two different doses for accelerated approval and the planned confirmatory trial. "Confirmation of benefit will be significantly delayed given that confirmatory trial has not begun enrolling patients." Poziotinib is an oral tyrosine kinase inhibitor that inhibits the activity of epidermal growth factor receptor (EGFR [HER1], HER2, and HER4) kinases. Seeking Alpha's Quant Rating views Spectrum (SPPI) as a hold.
분석 기사 • Sep 16

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Sep 09

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Spectrum Pharmaceuticals (NASDAQ:SPPI) stock jumped 10.4% afterhours on Friday after the U.S. Food and Drug Administration approved its Rolvedon injection. The injection is used to treat chemotherapy-induced neutropenia (abnormally low count of a type of neutrophils). SPPI said the FDA's nod marks the first novel long-acting GCSF (LA-GCSF) product approval in over 20 years. The company plans to commercially launch the injection in Q4. Shares of SPPI have fallen 18.2% YTD.
Seeking Alpha • Aug 21

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

We are circling back on a small biopharma named Spectrum Pharmaceuticals for the first time in a year and a half today. Spectrum has turned into a soap opera since then with two departures from the C-Suite, a CRL, and a significant workforce reduction. However, the company still is pushing two compounds towards potential FDA approval this year. An investment analysis follows in the paragraphs below. "Even as a solid rock is unshaken by the wind, so are the wise unshaken by praise or blame."― Dhammapada We last posted an article on Spectrum Pharmaceuticals (SPPI) back in March of 2021. At that time, we declined any investment recommendation on the shares but did promise to circle back on this name as its story developed. The company reported second-quarter results earlier this month and I have gotten a question or two from Seeking Alpha followers recently. Therefore, we will revisit this small biopharma company via the analysis below. Seeking Alpha Company Overview: Spectrum Pharmaceuticals focuses on developing and commercializing novel and targeted drug products with a primary focus in oncology. The company is headquartered just outside of Las Vegas. The stock currently trades around $1.25 a share and sports an approximate market capitalization of $250 million. Recent Developments: The company has been a non-stop soap opera since we last looked in on it. Its primary asset is ROLONTIS (eflapegrastim). Spectrum had submitted a marketing application on it for the treatment of neutropenia in patients receiving myelosuppressive anti-cancer drugs. This candidate has had a rocky ride, to say the least, towards FDA approval. First, the inspection of the manufacturing facility where ROLONTIS was to be made in South Korea by partner Hanmi was delayed thanks to the pandemic. March Company Presentation Then in August of 2021, the FDA slapped Spectrum's Biologics License Application or BLA with a Complete Response Letter or CRL. The CRL cited deficiencies related to manufacturing and indicated that a re-inspection will be necessary. Then in December of last year, the company announced its CEO was retiring which was followed by resignation of its CFO in February of this year. In between those management losses, Spectrum announced a restructuring that resulted in approximately 30% of its workforce being let go. The company also halted development of early-stage drug candidates to focus solely on pushing poziotinib and ROLONTIS across the finish line. These measures were projected to reduce annual cash burn by 20% to 25% and push the company's 'cash runway' into 2023. The company did resubmit its BLA for ROLONTIS in April and the FDA is scheduled to make a decision on its application on September 9th. January 2021 Company Presentation The FDA completed re-inspection of the manufacturing facility for ROLONTIS in August. Chemo-induced neutropenia impacts just over one million individuals in the United States. ROLONTIS would be the first drug in its class approved for this indication since Neulasta got the green light from the FDA in 2002. March Company Presentation March Company Presentation The approval path for poziotinib has been much smoother to this point. The compound is targeting patients with previously treated, locally advanced or metastatic non-small cell lung cancer, harboring HER2 exon 20 insertion mutations. This drug candidate is an orally administered, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 with exon 20 insertion mutations. Poziotinib has fast track designation and is on an accelerated approval pathway for this indication. The NDA was submitted some ago has a PDUFA date of November 24th of this year. It is important to note Poziotinib has a much smaller potential market than ROLONTIS and the company will have to demonstrate the compound has an overall risk benefit and clinical relevance based on its 'ZENITH' study to the FDA to garner approval. A randomized confirmatory trial is currently ongoing. A critical phase 2 trial in 2nd line NSCLC patients with EGFR exon 20 mutations around Poziotinib did not meet its primary endpoint of ORR in one of its cohorts early in 2020. Analyst Commentary & Balance Sheet: Since second quarter results posted, B. Riley Financial ($4 price target), H.C. Wainwright ($10 price target) and JMP Securities ($4 price target) have all reiterated Buy ratings on SPPI.
Seeking Alpha • Aug 10

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Spectrum Pharmaceuticals (NASDAQ:SPPI) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.10 (+60.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 2 years, SPPI has beaten EPS estimates 38% of the time and has beaten revenue estimates 13% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward.
분석 기사 • Jun 04

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 25

Spectrum Pharmaceuticals: Some Last Words

A spate of bad luck has destroyed SPPI stock. CEO and CFO have both resigned. Even if, somehow, ROLONTIS gets approved, they don't have the cash to commercialize.
분석 기사 • Oct 05

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 12

Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity

SPPI received a surprise CRL for rolontis. This could be resolved before the year is out, but there is no real clarity. The company does have enough cash to last it for a year or more.
Seeking Alpha • Jul 29

Spectrum's Big Approval: Any Day Now

The FDA completed the inspection of Hanmi's Korean facility almost a month ago. Approval should happen any day now. Rolontis is targeting a $3bn+ market.
분석 기사 • May 31

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Feb 12

We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Dec 21

Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like

A look at the shareholders of Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) can tell us which group is most powerful...

매출 및 비용 세부 내역

Spectrum Pharmaceuticals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NasdaqCM:SPPI 매출, 비용 및 순이익 (USD Millions)
날짜매출순이익일반관리비연구개발비
31 Mar 2326-684343
31 Dec 2210-783942
30 Sep 220-1064251
30 Jun 220-1174559
31 Mar 220-1385672
31 Dec 210-1586087
30 Sep 210-1695788
30 Jun 210-1846092
31 Mar 210-1666085
31 Dec 200-1716081
30 Sep 200-1626085
30 Jun 200-1405878
31 Mar 200-1366074
31 Dec 190-1356079
30 Sep 190-1486186
30 Jun 190-1916184
31 Mar 190-1476083
31 Dec 180-1276375
30 Sep 1829-1026867
30 Jun 1865-517466
31 Mar 1899-877564
31 Dec 170-1016552
30 Sep 17135-817263
30 Jun 17132-817359
31 Mar 17132-848358
31 Dec 16146-708659
30 Sep 16162-559256
30 Jun 16157-569255
31 Mar 16168-358750
31 Dec 15163-538851
30 Sep 15164-509050
30 Jun 15183-429454
31 Mar 15185-449774
31 Dec 14187-469770
30 Sep 14176-829866
30 Jun 14171-789965
31 Mar 14157-849546
31 Dec 13156-629447
30 Sep 13184-158650
30 Jun 13211148446
31 Mar 13247428645
31 Dec 12268948342
30 Sep 12251959034

양질의 수익: SPPI 은(는) 현재 수익성이 없습니다.

이익 마진 증가: SPPI는 현재 수익성이 없습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: SPPI은 수익성이 없으며 지난 5년 동안 손실이 연평균 0.5% 증가했습니다.

성장 가속화: 현재 수익성이 없어 지난 1년간 SPPI의 수익 성장률을 5년 평균과 비교할 수 없습니다.

수익 대 산업: SPPI은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.

자기자본이익률

높은 ROE: SPPI는 현재 수익성이 없으므로 자본 수익률이 음수(-252.59%)입니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2023/08/02 00:29
종가2023/07/31 00:00
수익2023/03/31
연간 수익2022/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Spectrum Pharmaceuticals, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
David BuckB. Riley Securities, Inc.
Alethia YoungCantor Fitzgerald & Co.
Reni BenjaminCitizens JMP Securities, LLC